Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients
Morote Robles, Juan (Hospital Universitari Vall d'Hebron)
Comas Reixach, Imma (Hospital Universitari Vall d'Hebron)
Ferrer Costa, Roser (Hospital Universitari Vall d'Hebron)
Planas, Jacques (Hospital Universitari Vall d'Hebron)
Celma, Ana (Hospital Universitari Vall d'Hebron)
Regis, Lucas (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona

Data:	2017
Resum:	Luteinizing hormone-releasing hormone (LH-RH) agonists are the standard for androgen deprivation therapy (ADT) in prostate cancer (PCa) patients. Current guidelines recommend serum testosterone measurement to assess the efficacy of ADT and to define castration resistance. However, serum testosterone does not reflect the exclusive effect of castration due to its extratesticular production. The aim of this study is to analyze if serum LH reflects better than serum testosterone the activity of LH-RH agonists. Serum LH and serum testosterone were measured with chemiluminescent immunoassay (CLIA) in a cohort study of 1091 participants: 488 PCa patients "on LH-RH agonists", 303 "off LH-RH agonist" in whom LH-RH agonists were withdrawn, and 350 men with PCa suspicion "no LH-RH agonist" who never received LH-RH agonists. In a validation cohort of 147 PCa patients, 124 on "LH-RH agonists" and 19 "off LH-RH agonists", serum testosterone was also measured with liquid chromatography and tandem mass spectrometry (LC MSMS). The area under the curve (AUC) to distinguish patients "on versus off LH-RH agonists" was 0. 997 for serum LH and 0. 740 for serum testosterone, P < 0. 001. The 97. 5 percentile of serum LH in patients "on LH-RH agonists" was 0. 97 U/L, been the most efficient threshold 1. 1 U/L. The AUCs for serum LH, testosterone measured with CLIA and with LC MSMS, in the validation cohort, were respectively 1. 000, 0. 646 and 0. 814, P < 0. 001. The efficacy to distinguish patients "on versus off LH-RH agonists" was 98. 6%, 78. 3%, and 89. 5% respectively, using 1. 1 U/L as threshold for serum LH and 50 ng/dL for serum testosterone regardless the method. Serum LH is more accurate than serum testosterone regardless the method, to distinguish patients "on versus off LH-RH agonists". The castrate level of serum LH is 1. 1 U/l. These findings suggest that assessment of LH-RH agonist efficacy and castration resistance definition should be reviewed.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Prostate cancer ; Androgen deprivation therapy ; LH-RH agonist ; Testosterone ; Luteinizing hormone
Publicat a:	Journal of Biomedical Science, Vol. 24 (october 2017) , ISSN 1423-0127

DOI: 10.1186/s12929-017-0386-0
PMID: 29058606

6 p, 759.5 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats